Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | ESRRB | O95718 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESRRG | P62508 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967586 | 0.92 | ESRRB (0.42) | OPRM1OPRL1ESRRBESR1ESRRG | |
| SCHEMBL1731711 | 0.86 | KDM4E (0.37) | OPRM1OPRL1ESRRBESR1ESRRG | |
| SCHEMBL19159867 | 0.78 | OPRM1 (0.57) | OPRM1OPRL1TSHRS1PR4S1PR1 | |
| SCHEMBL23420505 | 0.78 | KEAP1 (0.43) | OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL23421790 | 0.78 | OPRM1 (0.40) | OPRM1OPRL1TSHRS1PR4S1PR1 | |
| SCHEMBL19159433 | 0.77 | OPRM1 (0.52) | OPRM1OPRL1S1PR4S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL25364779 | 0.77 | ESRRB (0.39) | ESRRBESR1ESRRGTSHR | |
| SCHEMBL4489191 | 0.77 | HRH3 (0.34) | OPRM1TSHRS1PR4S1PR1S1PR3 | |
| SCHEMBL14967930 | 0.76 | TSHR (0.40) | TSHR | |
| SCHEMBL14968315 | 0.75 | HRH2 (0.46) | TSHRS1PR4S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973407-B1 | SPIRO COMPOUNDS AND METHODS OF USE | CHEN GUOQING PAUL (US) | 2011-11-23 | — | — | EP | claimed |
| US-20110237794-A1 | Spiro Compounds And Methods Of Use | CHEN GUOQING PAUL | 2011-09-29 | — | — | US | claimed |
| US-20070167470-A1 | Spiro compounds and methods of use | CHEN GUOQING P | 2007-07-19 | — | — | US | claimed |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-20210008045-A1 | PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| EP-3154957-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES | FUNDACION PARA LA INVESTIG MEDICA APLICADA (ES) | 2019-11-20 | — | — | EP | disclosed |
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110237794-A1 | Spiro Compounds And Methods Of Use | CHEN GUOQING PAUL | 2011-09-29 | — | — | US | disclosed |
| US-7977346-B2 | Spiro compounds and methods of use | CHEN GUOQING PAUL | 2011-07-12 | — | — | US | disclosed |
| EP-1973407-A2 | SPIRO COMPOUNDS AND METHODS OF USE | Chen, Guoqing Paul (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007084875-A2 | SPIRO COMPOUNDS AND METHODS OF USE | CHEN GUOQING PAUL (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167470-A1 | Spiro compounds and methods of use | CHEN GUOQING P | 2007-07-19 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | OPRM1 358/4885OPRL1 1512/4885ESRRB 3280/4885 |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | FURIN, PEPD, PIN1 | OPRM1 469/4885OPRL1 3020/4885ESRRB 4733/4885 |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | FURIN, PEPD, PIN1 | OPRM1 469/4885OPRL1 3020/4885ESRRB 4733/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | OPRM1 358/4885OPRL1 1540/4885ESRRB 3300/4885 |
| US-20110237794-A1 | Spiro Compounds And Methods Of Use | TEK, KDR, EGFR | OPRM1 2371/4885OPRL1 965/4885ESRRB 157/4885 |
| US-20070167470-A1 | Spiro compounds and methods of use | TEK, KDR, EGFR | OPRM1 2371/4885OPRL1 965/4885ESRRB 157/4885 |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | TPMT, MAPT, TLR4 | OPRM1 355/4885OPRL1 3066/4885ESRRB 4078/4885 |
| US-20210008045-A1 | PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF | TPMT, PBRM1, PGM2 | OPRM1 80/4885OPRL1 2074/4885ESRRB 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.